Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo

References

• LorenzoJ, HorowitzM, ChoiY. Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 2008;29(4):403–440.18451259
   PubMed Web of Science ®Google Scholar
• HuB, SunX, YangY, et al. Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling. FASEB J. 2019;33(2):2574–2586. doi:10.1096/fj.201800920R30285579
   PubMed Web of Science ®Google Scholar
• YuanG, LianZ, LiuQ, et al. Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis. Cancer Lett. 2019;443:135–144. doi:10.1016/j.canlet.2018.11.03830540926
   PubMed Web of Science ®Google Scholar
• JiangY, SangW, WangC, et al. Oxymatrine exerts protective effects on osteoarthritis via modulating chondrocyte homoeostasis and suppressing osteoclastogenesis. J Cell Mol Med. 2018;22(8):3941–3954. doi:10.1111/jcmm.13674
   PubMed Web of Science ®Google Scholar
• BlackDM, AbrahamsenB, BouxseinML, EinhornT, NapoliN. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019;40(2):333–368. doi:10.1210/er.2018-0000130169557
   PubMed Web of Science ®Google Scholar
• WottonCJ, GreenJ, BrownA, et al. Use of oral bisphosphonates and risk of hospital admission with osteonecrosis of the jaw: large prospective cohort study in UK women. Bone. 2019;124:69–74. doi:10.1016/j.bone.2019.04.00330959190
   PubMed Web of Science ®Google Scholar
• KennelKA, DrakeMT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009;84(7):632–637; quiz 638. doi:10.1016/S0025-6196(11)60752-0
   PubMed Web of Science ®Google Scholar
• RoodmanGD. Cell biology of the osteoclast. Exp Hematol. 1999;27(8):1229–1241. doi:10.1016/S0301-472X(99)00061-210428500
   PubMed Web of Science ®Google Scholar
• AraiF, MiyamotoT, OhnedaO, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of C-Fms and receptor activator of nuclear factor κb (rank) receptors. J Exp Med. 1999;190(12):1741. doi:10.1084/jem.190.12.174110601350
   PubMed Web of Science ®Google Scholar
• TakayanagiH. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292. doi:10.1038/nri206217380158
   PubMed Web of Science ®Google Scholar
• MizukamiJ, TakaesuG, AkatsukaH, et al. Receptor activator of NF-κB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol. 2002;22(4):992–1000. doi:10.1128/MCB.22.4.992-1000.200211809792
   PubMed Web of Science ®Google Scholar
• DarnayBG, BesseA, PoblenzAT, LamotheB, JacobyJJ. TRAFs in RANK signaling In: WuH, editor. TNF Receptor Associated Factors (Trafs). New York: Springer New York; 2007:152–159.
   Google Scholar
• WongBR, BesserD, KimN, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell. 1999;4(6):1041–1049. doi:10.1016/S1097-2765(00)80232-410635328
   PubMed Web of Science ®Google Scholar
• Ha KimJ, KimN. Regulation of NFATc1 in osteoclast differentiation. J Bone Metabol. 2014;21(4):233–241. doi:10.11005/jbm.2014.21.4.233
   PubMedGoogle Scholar
• KimMS, YangY-M, SonA, et al. RANKL-mediated ROS pathway that induces long-lasting Ca2+ oscillations essential for osteoclastogenesis. J Biol Chem. 2010;285(10):6913–6921.20048168
   PubMed Web of Science ®Google Scholar
• ShenS, ZhangY, ZhangR, GongX. Sarsasapogenin induces apoptosis via the reactive oxygen species-mediated mitochondrial pathway and ER stress pathway in HeLa cells. Biochem Biophys Res Commun. 2013;441(2):519–524. doi:10.1016/j.bbrc.2013.10.10124383086
   PubMed Web of Science ®Google Scholar
• LimSM, JeongJJ, KangGD, KimKA, ChoiHS, KimDH. Timosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balance. Int Immunopharmacol. 2015;25(2):493–503. doi:10.1016/j.intimp.2015.02.01625698557
   PubMed Web of Science ®Google Scholar
• MaD, ZhangJ, SugaharaK, SagaraY, KodamaH. Effect of sarsasapogenin and its derivatives on the stimulus coupled responses of human neutrophils. Clin Chim Acta. 2001;314(1–2):107–112. doi:10.1016/S0009-8981(01)00638-611718685
   PubMed Web of Science ®Google Scholar
• ParkBK, SoKS, KoHJ, et al. Therapeutic potential of the rhizomes of anemarrhena asphodeloides and timosaponin A-III in an animal model of lipopolysaccharide-induced lung inflammation. Biomol Ther (Seoul). 2018;26(6):553–559. doi:10.4062/biomolther.2017.24929925223
   PubMed Web of Science ®Google Scholar
• BaoW, PanH, LuM, NiY, ZhangR, GongX. The apoptotic effect of sarsasapogenin from Anemarrhena asphodeloides on HepG2 human hepatoma cells. Cell Biol Int. 2007;31(9):887–892. doi:10.1016/j.cellbi.2007.02.00117400003
   PubMed Web of Science ®Google Scholar
• DongD, ZhouNN, LiuRX, et al. Sarsasapogenin-AA13 inhibits LPS-induced inflammatory responses in macrophage cells in vitro and relieves dimethylbenzene-induced ear edema in mice. Acta Pharmacol Sin. 2017;38(5):699–709. doi:10.1038/aps.2016.18028239159
   PubMed Web of Science ®Google Scholar
• HuangC, DongD, JiaoQ, PanH, MaL, WangR. Sarsasapogenin-AA13 ameliorates Aβ-induced cognitive deficits via improving neuroglial capacity on Aβ clearance and antiinflammation. CNS Neurosci Ther. 2017;23(6):498–509. doi:10.1111/cns.1269728466999
   PubMed Web of Science ®Google Scholar
• ZhangT, ZhaoK, HanW, et al. Deguelin inhibits RANKL-induced osteoclastogenesis in vitro and prevents inflammation-mediated bone loss in vivo. J Cell Physiol. 2019;234(3):2719–2729. doi:10.1002/jcp.2708730078209
   PubMed Web of Science ®Google Scholar
• NichC, LangloisJ, MarchadierA, et al. Oestrogen deficiency modulates particle-induced osteolysis. Arthritis Res Ther. 2011;13(3):R100. doi:10.1186/ar338121696618
   PubMedGoogle Scholar
• YangH, XuY, ZhuM, et al. Inhibition of titanium-particle-induced inflammatory osteolysis after local administration of dopamine and suppression of osteoclastogenesis via D2-like receptor signaling pathway. Biomaterials. 2016;80:1–10. doi:10.1016/j.biomaterials.2015.11.04626695376
   PubMed Web of Science ®Google Scholar
• BoyleWJ, SimonetWS, LaceyDL. Osteoclast differentiation and activation. Nature. 2003;423:337. doi:10.1038/nature0165812748652
   PubMed Web of Science ®Google Scholar
• TakayanagiH. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med. 2005;83(3):170–179. doi:10.1007/s00109-004-0612-615776286
   PubMed Web of Science ®Google Scholar
• TakayanagiH, KimS, KogaT, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889–901. doi:10.1016/S1534-5807(02)00369-612479813
   PubMed Web of Science ®Google Scholar
• WagnerEF. Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). Ann Rheum Dis. 2010;69(Suppl 1):i86. doi:10.1136/ard.2009.11939619995753
   PubMed Web of Science ®Google Scholar
• GrigoriadisA, WangZ, CecchiniM, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 1994;266(5184):443–448. doi:10.1126/science.79396857939685
   PubMed Web of Science ®Google Scholar
• KashiwadaM, ShirakataY, InoueJ-I, et al. Tumor necrosis factor receptor–associated factor 6 (TRAF6) stimulates extracellular signal–regulated kinase (ERK) activity in CD40 signaling along a Ras-independent pathway. J Exp Med. 1998;187(2):237–244. doi:10.1084/jem.187.2.2379432981
   PubMed Web of Science ®Google Scholar
• KhoslaS. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142(12):5050–5055. doi:10.1210/endo.142.12.853611713196
   PubMed Web of Science ®Google Scholar
• CackowskiFC, AndersonJL, PatreneKD, et al. Osteoclasts are important for bone angiogenesis. Blood. 2010;115(1):140. doi:10.1182/blood-2009-08-23762819887675
   PubMed Web of Science ®Google Scholar
• KimK, LeeS-H, Ha KimJ, ChoiY, KimN. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol. 2008;22(1):176–185. doi:10.1210/me.2007-023717885208
   PubMedGoogle Scholar
• AngelNZ, WalshN, ForwoodMR, OstrowskiMC, CassadyAI, HumeDA. Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. J Bone Miner Res. 2000;15(1):103–110. doi:10.1359/jbmr.2000.15.1.10310646119
   PubMed Web of Science ®Google Scholar
• GelbBD, ShiG-P, ChapmanHA, DesnickRJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236. doi:10.1126/science.273.5279.12368703060
   PubMed Web of Science ®Google Scholar
• SapkotaM, LiL, KimS-W, SohY. Thymol inhibits RANKL-induced osteoclastogenesis in RAW264.7 and BMM cells and LPS-induced bone loss in mice. Food Chem Toxicol. 2018;120:418–429. doi:10.1016/j.fct.2018.07.03230048646
   PubMed Web of Science ®Google Scholar
• WangB, HaoD, ZhangZ, et al. Inhibition effects of a natural inhibitor on RANKL downstream cellular signalling cascades cross-talking. J Cell Mol Med. 2018;22(9):4236–4242. doi:10.1111/jcmm.1370329911332
   PubMed Web of Science ®Google Scholar
• KimJ-M, LeeJ-H, LeeG-S, et al. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells. BMC Complement Altern Med. 2017;17(1):164. doi:10.1186/s12906-016-1550-x28335757
   PubMed Web of Science ®Google Scholar
• ZhaiZJ, LiHW, LiuGW, et al. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Br J Pharmacol. 2014;171(3):663–675. doi:10.1111/bph.1246324125472
   PubMed Web of Science ®Google Scholar
• WangQ, YaoL, XuK, et al. Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis. J Cell Mol Med. 2019;23(1):380–394.30338925
   PubMed Web of Science ®Google Scholar
• WuZ, WuH, LiC, et al. Daphnetin attenuates LPS-induced osteolysis and RANKL mediated osteoclastogenesis through suppression of ERK and NFATc1 pathways. J Cell Physiol. 2019;234(10):17812–17823. doi:10.1002/jcp.2840830815894
   PubMed Web of Science ®Google Scholar